• Small Molecules
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Who we are

We are an innovation-led contract research, development and manufacturing organization offering integrated scientific services from early discovery to commercial supply.

What we do

We offer clients a customized end-to-end solution to fulfil their R&D and manufacturing requirements. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations.

Discovery

Our Discovery Services span the entire spectrum of early stage research from target …

Development

Our Development Services encompass activities from pre-clinical to clinical trials…

Manufacturing

Our Manufacturing services include cGMP-compliant facilities for clinical supplies, registration batches…

Dedicated Centers

Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support…

InstaVisit - Visit Syngene Virtually

Syngene InstaVisit is an interactive virtual experience designed to give you a 360 degree view of Syngene’s world-class facilities and capabilities. The platform allows you to change your perspective, look around and zoom in as we take you on a guided tour of Syngene’s labs.

Visit Syngene virtually with a 360 degree view of Syngene’s world-class facilities and capabilities
0

Clients

0

Collaborations with the top 10 Pharma/Biotech companies

0 +

Experienced Scientists

0

Mn sq. ft. of R&D and manufacturing infrastructure

0 +

Patents 

Syngene sees ‘mid-teen’ growth this fiscal on strong pent-up demand

News
17th Jun, 2021

Syngene appoints Sanjeev Sukumaran as CHRO

Press Release
2nd Jun, 2021

Syngene reports revenue from operations growth of 13% in the fourth quarter; 12% for the full year

Press Release
26th Apr, 2021

Design of Experiment (DoE) – An efficient tool for process optimization

DoE is achieving increasing acceptance in the pharmaceutical sector as it is being seen as an efficient tool for process optimization, including helping to develop quality products.

Things you may not know about continuous flow chemistry

The continuous flow chemistry processes established in the lab can now be readily transferred to the production facilities and scaled up for commercial use without substantially altering reaction conditions.

Complimentary techniques for determining Relative response factor of non- isolated impurities

Understanding the concept behind determining UV RRF of non-isolated impurities using High Performance Liquid Chromatography and Nuclear Magnetic Resonance

Upcoming events

22nd - 24th June, 2021
Virtual
29th June - 01st July, 2021
Virtual

Corporate social responsibility

To strive towards developing and sustaining healthy and empowered communities by improving the quality of life.

Syngene International Ltd

+1.35(0.32%)+1.35(0.32%)

Governance

Behind consistent growth is good governance

Careers

Discover a world of opportunities

Annual Reports

Touching a billon lives through innnovation

To download, Please share your details